1. Home
  2. DEO vs EW Comparison

DEO vs EW Comparison

Compare DEO & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diageo plc

DEO

Diageo plc

HOLD

Current Price

$81.87

Market Cap

49.3B

ML Signal

HOLD

Logo Edwards Lifesciences Corporation

EW

Edwards Lifesciences Corporation

HOLD

Current Price

$81.78

Market Cap

50.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DEO
EW
Founded
1886
1958
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Industrial Specialties
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.3B
50.2B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
DEO
EW
Price
$81.87
$81.78
Analyst Decision
Buy
Buy
Analyst Count
2
21
Target Price
$109.00
$96.47
AVG Volume (30 Days)
2.0M
4.9M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
4.94%
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.83
Revenue
N/A
$6,067,600,000.00
Revenue This Year
$3.01
$13.39
Revenue Next Year
$1.23
$9.78
P/E Ratio
$90.04
$45.80
Revenue Growth
N/A
11.55
52 Week Low
$80.79
$65.94
52 Week High
$116.69
$87.89

Technical Indicators

Market Signals
Indicator
DEO
EW
Relative Strength Index (RSI) 34.53 47.53
Support Level N/A $81.61
Resistance Level $92.24 $82.64
Average True Range (ATR) 1.97 2.17
MACD -1.85 0.36
Stochastic Oscillator 5.05 49.59

Price Performance

Historical Comparison
DEO
EW

About DEO Diageo plc

Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio. The firm has also shed noncore brands over the years, including the majority of its wine assets in 2015.

About EW Edwards Lifesciences Corporation

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Share on Social Networks: